T-cell malignancies following CAR T-Cell therapy: insights from the FDA Adverse Event Reporting System (FAERS)
Axicabtagene ciloleucel and tisagenlecleucel may be associated with a higher reporting frequency of T-cell lymphoma than other drugs.
Authors
- Annalisa Capuano (ORCID: https://orcid.org/0000-0002-8653-2408)
- Rosanna Ruggiero
- Gabriella di Mauro (ORCID: https://orcid.org/0000-0001-5096-7277)
- Annamaria Mascolo (ORCID: https://orcid.org/0000-0003-2554-0065)
- Nunzia Balzano
- Cristina Scavone (ORCID: https://orcid.org/0000-0002-9216-922X)
- Raffaella Di Napoli (ORCID: https://orcid.org/0009-0009-4497-3836)
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- Regione Campania (IT)
- Santobono Children's Hospital (IT)
- Link Campus University (IT)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1080/14740338.2024.2443965
- Citations
- 3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.85